These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26052807)

  • 1. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
    Shonberg J; Draper-Joyce C; Mistry SN; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2015 Jul; 58(13):5287-307. PubMed ID: 26052807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.
    Mistry SN; Shonberg J; Draper-Joyce CJ; Klein Herenbrink C; Michino M; Shi L; Christopoulos A; Capuano B; Scammells PJ; Lane JR
    J Med Chem; 2015 Sep; 58(17):6819-43. PubMed ID: 26258690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtle Modifications to the Indole-2-carboxamide Motif of the Negative Allosteric Modulator N-(( trans)-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1 H)-yl)ethyl)cyclohexyl)-1 H-indole-2-carboxamide (SB269652) Yield Dramatic Changes in Pharmacological Activity at the Dopamine D
    Kopinathan A; Draper-Joyce C; Szabo M; Christopoulos A; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2019 Jan; 62(1):371-377. PubMed ID: 29890071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D
    Draper-Joyce CJ; Michino M; Verma RK; Klein Herenbrink C; Shonberg J; Kopinathan A; Scammells PJ; Capuano B; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Biochem Pharmacol; 2018 Feb; 148():315-328. PubMed ID: 29325769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.
    Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L
    PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The First Negative Allosteric Modulator for Dopamine D
    Rossi M; Fasciani I; Marampon F; Maggio R; Scarselli M
    Mol Pharmacol; 2017 Jun; 91(6):586-594. PubMed ID: 28265019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A structure-activity analysis of biased agonism at the dopamine D2 receptor.
    Shonberg J; Herenbrink CK; López L; Christopoulos A; Scammells PJ; Capuano B; Lane JR
    J Med Chem; 2013 Nov; 56(22):9199-221. PubMed ID: 24138311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive binding properties of the negative allosteric modulator, [
    Fasciani I; Pietrantoni I; Rossi M; Mannoury la Cour C; Aloisi G; Marampon F; Scarselli M; Millan MJ; Maggio R
    Eur J Pharmacol; 2018 Jan; 819():181-189. PubMed ID: 29223348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.
    Silvano E; Millan MJ; Mannoury la Cour C; Han Y; Duan L; Griffin SA; Luedtke RR; Aloisi G; Rossi M; Zazzeroni F; Javitch JA; Maggio R
    Mol Pharmacol; 2010 Nov; 78(5):925-34. PubMed ID: 20702763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new mechanism of allostery in a G protein-coupled receptor dimer.
    Lane JR; Donthamsetti P; Shonberg J; Draper-Joyce CJ; Dentry S; Michino M; Shi L; López L; Scammells PJ; Capuano B; Sexton PM; Javitch JA; Christopoulos A
    Nat Chem Biol; 2014 Sep; 10(9):745-52. PubMed ID: 25108820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D
    Fyfe TJ; Zarzycka B; Lim HD; Kellam B; Mistry SN; Katrich V; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2019 Jan; 62(1):174-206. PubMed ID: 29683325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1).
    Khurana L; Ali HI; Olszewska T; Ahn KH; Damaraju A; Kendall DA; Lu D
    J Med Chem; 2014 Apr; 57(7):3040-52. PubMed ID: 24635495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
    Andersen K; Liljefors T; Hyttel J; Perregaard J
    J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1).
    Mahmoud MM; Ali HI; Ahn KH; Damaraju A; Samala S; Pulipati VK; Kolluru S; Kendall DA; Lu D
    J Med Chem; 2013 Oct; 56(20):7965-75. PubMed ID: 24053617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D
    Kumar V; Moritz AE; Keck TM; Bonifazi A; Ellenberger MP; Sibley CD; Free RB; Shi L; Lane JR; Sibley DR; Newman AH
    J Med Chem; 2017 Feb; 60(4):1478-1494. PubMed ID: 28186762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.
    Szabo M; Klein Herenbrink C; Christopoulos A; Lane JR; Capuano B
    J Med Chem; 2014 Jun; 57(11):4924-39. PubMed ID: 24827597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.
    Kopinathan A; Scammells PJ; Lane JR; Capuano B
    Future Med Chem; 2016 Jul; 8(11):1349-72. PubMed ID: 27357619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology.
    Schetz JA; Benjamin PS; Sibley DR
    Mol Pharmacol; 2000 Jan; 57(1):144-52. PubMed ID: 10617689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.